Alessia Celeste Bocchino

Dr. Alessia Celeste Bocchino

University of Cagliari, Cagliari, Sardegna, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
ABAlessia Celeste Bocchino
Alessia Celeste Bocchino
MPMarta Pezzoli
Marta Pezzoli
Juan Ignacio Martínez-SalamancaJuan Ignacio Martínez-Salamanca
Juan Ignacio Martínez-Salamanca
Giorgio Ivan RussoGiorgio Ivan Russo
Giorgio Ivan Russo
AGArturo Lo Giudice
Arturo Lo Giudice
Andrea CocciAndrea Cocci
Andrea Cocci
Bocchino AC, et al. Investig Clin Urol. 2023 Feb;64:e14. https://doi.org/10.4111/icu.20220327

26 November 2021 in Urology Research and Practice
Verified
Journal Article
Open access
Andrea CocciAndrea Cocci
Andrea Cocci
ABAlessia Celeste Bocchino
Alessia Celeste Bocchino
GCGianmartin Cito
Gianmartin Cito
ALAntonello De Lisa
Antonello De Lisa
Giorgio Ivan RussoGiorgio Ivan Russo
Giorgio Ivan Russo
BSBhaskar K Somani
Bhaskar K Somani
The aim of this study was to review the available literature on the efficacy and safety of the Rezum system for the treatment of symptomatic benign prostatic hyperplasia (BPH). A revision of literature up to January 2021 was carried out. Medline, Scopus, Web of Science, and PubMed archives were screened to identify all the relevant studies investigating the role of Rezum in the treatment of BPH. Randomized controlled trial (RCT), retrospective, prospective, observational, and comparative studies were included. Finally, 17 studies were included, five of which reporting data of a double blind Rezum RCT. Overall, 1,451 patients underwent Rezum procedure. All the studies performed a minimum of 3 months follow-up. Preoperatively, the mean International Prostate Symptom Score (IPSS) score was 19.8, mean Qmax was 9.2mL s1, and mean PVR was 142 cc. At 3 months after surgery, the mean IPSS score was 1.5, mean Qmax was 13.7mL s1, and mean PVR was 74 cc. Six studies investigated sexual function, most of them using the International Index of Erectile Function (IIEF)-5 questionnaire and a few also the Male Sexual Health Questionnaire (MSHQ). Preoperative mean IIEF-5 score was 18.5, and the mean MSHQ score was 7.4. At the 3 months follow-up, the mean IIEF-5 score was 16.4, and the mean MSHQ score was 9.62. None of the studies reported intraoperative complications. Rezum system is a novel minimally invasive treatment for symptomatic BPH using transurethral water vapor thermal energy. It represents a cost-effective and safe procedure with durable relief of lower urinary tract symptom, preservation of sexual function, low complications rate, and short recovery time. Cite this article as: Cocci A, Bocchino AC, Cito G, et al. Role of Rezum in the treatment of benign prostate hyperplasia: A review of the literature. Turk J Urol. 2021; 47(6): 452-460

1 January 2024 in Urology Research and Practice
Verified
Journal Article
Open access
ABAlessia Celeste Bocchino
Alessia Celeste Bocchino
Andrea CocciAndrea Cocci
Andrea Cocci
MPMarta Pezzoli
Marta Pezzoli
Antonio EliaAntonio Elia
Antonio Elia
LLLuca Landi
Luca Landi
LMLorenzo Masieri
Lorenzo Masieri
Objective: This study aims to evaluate long-term functional, sexual, and cosmetic outcomes in adult patients who underwent hypospadias repair during childhood at a national highly specialized pediatric hospital. Methods: Medical records of pediatric patients who had undergone surgical repair of hypospadias between 1993 and 2004 at Meyer Children Hospital of Florence were reviewed. Adult patients were contacted by telephone between July and August 2021 and invited to participate. Long-term surgical outcomes were assessed focusing on complications and reinterventions, and 3 validated questionnaires on urinary function, erectile function, and penile cosmetic appearance were administered. Results: From January 1993 to December 2004, a total of 799 patients with hypospadias underwent repair surgery. Two hundred thirty-nine patients gave consent to be included in the study. Follow-ups occurred between 17 and 28 years after the first surgery. Most patients had anterior localization of hypospadias (210/239) and associated penile curvature (132/239). The most frequent surgery for hypospadias repair was meatal advancement and glanduloplasty incorporated (MAGPI) (88/239), and the most used surgical treatment for penile curvature was the Nesbit technique (49/132). The complication rate was 27% (65/239) in an average time of 4.7 years, and 48 surgical procedures have been performed to treat them. At follow-up, the mean IPSS was 0.96 ± 1.97, the mean IIEF-5 score was 24.10 ± 1.02, and the mean HOSE score was 15.47 ± 0.45. Patients who underwent reintervention reported a lower IPSS than those who underwent only 1 surgery (0.29 vs. 1.16). Conclusion: Hypospadias repair during childhood leads to rather normal urinary and sexual function and penile cosmetic appearance in adolescence and adulthood. Cite this article as: Bocchino AC, Cocci A, Pezzoli M, et al. Long-term functional, sexual, and cosmetic outcomes in adult patients who underwent hypospadias repair during childhood at a highly specialized Italian Pediatric Hospital. Urol Res Pract. 2024;50(2):127-133.

23 August 2022 in Uro
Verified
Journal Article
Open access
PDF file
ABAlessia Celeste Bocchino
Alessia Celeste Bocchino
Andrea CocciAndrea Cocci
Andrea Cocci
AZAlessandro Zucchi
Alessandro Zucchi
RBRiccardo Bartoletti
Riccardo Bartoletti
ALAntonello De Lisa
Antonello De Lisa
GMGirolamo Morelli
Girolamo Morelli
Gender Affirmation Surgeries (GASs), erstwhile called Sex Reassignment Surgeries (SRSs), may be necessary for transgender individuals to change their bodily sexual characteristics and thereby affirm their gender identity. GASs encompass all medically necessary interventions to relieve gender dysphoria and should be available to patients who wish to, and who meet the surgical criteria of the World Professional Association for Transgender Health (WPATH) and Standards of Care (SOC). The comprehensive clinical assessment involves many health specialists, including general practitioners, psychologists, psychiatrists, speech therapists, endocrinologists, surgeons, anesthesiologists, nurses, and other healthcare professionals. To define the patients’ complex care needs and their objectives, high-volume specialized centers, accredited training programs, skilled surgeons and health professionals specializing in transgender care within a multidisciplinary team are essential. Currently, the most prominent challenges are related to ethical issues such as the treatment of underage individuals, fertility, parenting and the potential for regret after GAS. Finally, although GAS has been practiced for more than half a century, data on long-term follow-up represents a further topic for investigation.